Stay updated on MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.

Latest updates to the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page
- Check3 days agoChange DetectedThe clinical-trial record for MEDI4736 and tremelimumab in gastric or gastroesophageal junction adenocarcinoma is displayed, including study design, participant criteria, outcome measures, record dates, and study documents. The record identifies the study as completed and no longer recruiting participants.SummaryDifference75%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces NIH website transition updates and says the agency is adopting “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check30 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record, blocking access to the study details and attached documents. The error page includes a Home link for navigation.SummaryDifference20%

Stay in the know with updates to MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.